Picture loading failed.

Anti-EPCAM therapeutic antibody (Pre-made Oportuzumab biosimilar,scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-408-1mg 1mg 3090
GMP-Bios-ab-408-10mg 10mg 21890
GMP-Bios-ab-408-100mg 100mg 148000
GMP-Bios-ab-408-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EPCAM therapeutic antibody (Pre-made Oportuzumab biosimilar,scFv)
INN Name Oportuzumab
TargetEPCAM
FormatscFv
Derivation
Species ReactivityHuman
CH1 Isotypena
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesUniversity of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies
Conditions Approvedna
Conditions ActiveBladder cancer;Head and neck cancer
Conditions DiscontinuedLiver cancer;Ovarian cancer
Development Techna